A Shared Cancer Vaccine Passed Phase 3: Moderna +177%, Merck +12.6%

Before the U.S. market opened on August 19, two companies put out a joint release. It was short, and it contained no result.

Here is what it said: the individualized cancer vaccine that Moderna and Merck have been developing together hit the primary endpoint of its Phase 3 trial in melanoma patients whose tumors had been surgically removed. By how much — how far it cut the risk of the disease coming back — they did not say. "These data will be presented at an upcoming international medical meeting."

By the close, the two companies were worth $86 billion more than they had been the day before. On a release with no effect size in it.

What Was Actually in the Release

The trial is called INTerpath-001. It covers high-risk melanoma patients whose tumors were completely resected. Of 1,137 patients, two-thirds got Merck's Keytruda plus the vaccine and one-third got Keytruda alone. The vaccine is dosed every three weeks, up to nine doses; Keytruda every six weeks, up to nine cycles. Treatment runs about 56 weeks.

The release reports two results: a statistically significant improvement in time to recurrence, and the same in time to distant metastasis. Overall survival data are not yet mature.

The only numerical efficacy figure in the release belongs to the old Phase 2 study from 2023: a 49% reduction in the risk of recurrence or death across 157 patients. That study's confidence interval was very wide — it pointed in the right direction but had little to say about magnitude. The Phase 3's own numbers were not published.

With No Numbers, What Did the Market Read?

The mechanism here is statistical rather than medical.

A large clinical trial is opened and examined before it finishes, by an independent monitoring committee, on a schedule written before the first patient is enrolled. The key point: declaring victory early is harder than declaring it at the end.

RBC's analysts wrote it plainly: a readout they had expected at year-end arrived months early, so "the strength of the underlying data must have been compelling to trigger significance." TD Cowen called it a "landmark moment." William Blair upgraded Moderna.

That is an inference, not a certainty; the actual Phase 3 numbers may disappoint when they are presented. But it is what the market priced that morning.

The 2022 Partnership: Down the Middle

The vaccine's commercial history goes back four years. In October 2022, Merck exercised its option with Moderna and paid $250 million. What it bought was simple: all costs and all profits or losses on the drug would be shared equally, worldwide. Moderna manufactures; Merck runs the clinical program.

Every link in that chain runs for a single patient, and manufacturing is measured in weeks. This is not a drug sold off a shelf; it is a supply chain rebuilt per patient — and whether it scales is the most contested part of the story.

The Mechanism: Same Asset, Two Different Denominators

Now to the day's real lesson. If the drug is split down the middle, the value it creates should be split down the middle too. It was — but that is not how it looked on a screen.

Which is why a stock's daily percentage tells you far less about the size of the news than you think. A percentage measures the news relative to the company's existing size. More: What Is Market Capitalization?

One caveat is required: part of Merck's move blends into a health care sector that closed at a record the same day. Attributing the entire $42 billion to this trial is an interpretation, not a fact.

Why Merck Was So Pleased: The 2028 Problem

One line dominates Merck's income statement. Keytruda sold $31.7 billion in 2025 — 49% of the company's total revenue. A single drug, half a company.

And the first patent on that drug expires in December 2028.

Here is the distinction headlines keep collapsing. "The patent expires in 2028" does not mean the drug goes generic in 2029. Merck holds something like thirty patent families around Keytruda, covering composition, formulation and methods of use separately; some run to 2039. The subcutaneous formulation approved in September 2025 is protected to 2041. This is not a cliff, it is a slope — Bloomberg Intelligence expects sharp erosion nearer 2033 than 2029. Nobody can name a firm date.

That is where the vaccine matters to Merck. Intismeran is not given on its own; it is given only with Keytruda, inside a 56-week regimen. A regimen that sits at the center of a treatment protocol and carries its own patents means more to Merck than a new revenue line.

But this is not automatic either. Once exclusivity lapses, a biosimilar pembrolizumab could in principle substitute for branded Keytruda inside the same combination. Whether the regimen protects the brand depends on which product the approval attaches to and on what physicians choose. What the market priced was not a guarantee — it was a probability moving up.

Where the Wave Traveled

The move did not stay with the two owners.

What those bars say: BioNTech earns nothing from this trial. It is simply trying the same approach in its own programs. It rose 22% anyway — because what was being repriced was not one company's revenue but the odds that a method works.

The S&P 500 health care sector closed at a record the same day, while the semiconductor index fell 1.3% and Broadcom dropped 4%. The indices were caught between the two currents: SPY rose 0.23% while QQQ, which tracks the Nasdaq 100, slipped 0.20%. Separately, the U.S. Treasury said it would raise its long-dated buyback operations from $2 billion to at least $4 billion, and the 30-year yield backed off its highest level since 2007. Moderna was not the whole story of the day — only its largest move.

The 2025 line is the story's sharpest irony. This vaccine's technology belongs to the same family whose funding its own government cut a year earlier. The canceled contracts did not touch oncology; the text of that decision concerned infectious-disease vaccines. But a political climate directed at a technology discounts all of its branches at once.

The Other Side

What Is Left

Moderna's financial statements were untouched by this news. The company reported $145 million of revenue and a $782 million loss in the second quarter of 2026. It held $6.9 billion in cash at the end of June; operations consumed $1.16 billion in the first half, and a July settlement took another $950 million. Its own guidance is to finish the year with $4.7 billion to $5.2 billion. More: What Is Cash Flow?

So the $44.5 billion the market handed Moderna on August 19 is roughly nine times the cash the company expects to be holding at year-end. That money is not the counterpart of any revenue. It is the price of a probability.

On Merck's side what changed is not revenue but a calendar. 2028 is still there; only the distribution of what comes after it has shifted.

At index scale the day looks like nothing happened, and that is the point: the real move was not inside the index but between two stocks. The lesson from it applies to every session.

The second lesson sits in the release itself. What the market read that morning was not a number but a decision: an independent committee opening the trial early and calling it sufficient. Sometimes the most informative thing is not the figure disclosed, but when it was disclosed.

This article draws on the joint Merck–Moderna release of August 19, 2026, the companies' reported financial results, and coverage from BioPharma Dive, BioSpace, TIME and Benzinga. The Phase 3 effect sizes have not yet been published; the 49% figure cited here belongs to the smaller Phase 2 study reported in 2023. Closing prices and market values come from market data providers; intraday coverage carried lower percentages because the stock continued climbing into the close. Estimates of patent duration and revenue erosion vary across institutions.